Exclusivity topamax weight loss 100 mg men for Zyrtec in
and for Camptosar in as well as the loss of
exclusivity for Norvasc in Korea and Japan in and July
2008, respectively. Zyrtec, Camptosar and Norvasc fourth-quarter 2008
revenues decreased benazepril 5mg by $515 million ($263 million, $144 million and $108
million, respectively), compared elocon cv5 with the year-ago prescription medicines quarter. PFE - News) today reported financial results for
fourth-quarter and full-year valtrex 2008. This decrease was primarily attributable to
the negative impact of the loss tetracycline ear drops drop of U.S.
International
reported revenues antibiotic
were $7.1 billion, a decrease genital herpes of 1% compared with the
year-ago quarter, and reflect operational suntan beds and amoxicillin bed growth of 5%, which was more
than offset by.
For holistic arthritis treatment fourth-quarter 2008, the Company
recorded reported revenues of $12.3 billion, online pharmacies a decrease of 4% compared
with the year-ago quarter. Reported metformin and ovulation revenues were $5.3 billion in fourth-quarter online pharmacist 2008, antibiotic
a
decrease albuterol aerosol of 8% compared with the year-ago quarter. ($ in azithromycin
millions, except cyst pilonidal cephalexin per chemist share amounts)
Fourth-Quarter
Full-Year
2008
2007
polysporin triple antibiotic ointment side effects
Change
2008
tetracycline 2007
Change
cipralex and loosing amoxicillin and potassium clavulanate
weight Reported Revenues
$ 12,346
$ 12,870
(4%)
$ 48,296
$ 48,418
azithromycin
--
Reported Net Income
266
2,724
zithromax
drug store
(90%)
8,104
8,144
--
Reported mixing antibiotics and homeopathic medicine Diluted online pharmacy EPS
0.04
0.40
(90%)
1.20
1.17
3%
Adjusted Revenues(1)
azythromycin 12,311
12,795
(4%)
amoxicillin
48,341
48,209
--
Adjusted Income(1)
simvastatin medication
4,389
3,402
29%
16,366
15,113
8%
Adjusted Diluted EPS(1)
0.65
0.50
micardis hair texture
30%
2.42
2.18
11%
See end of text prior to tables for notes. In addition,
foreign exchange unfavorably impacted reported revenues by approximately
$380 million or 3%, partially offset by the solid performance of key
products.
There are no comments on this page. [Add comment]